REG - Nuformix PLC - Change of Accounting Reference Date

NuformixAnnouncement

13/03/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230313:nRSM6565Sa&default-theme=true

RNS Number : 6565S  Nuformix PLC  13 March 2023

13 March 2023

 

Nuformix plc

 

("Nuformix" or the "Company" or the "Group")

Change of Accounting Reference Date

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing, announces a
change to its accounting reference date and financial year end from 31 March
to 30 September with immediate effect.  Going forward the annual and interim
reports will be published each year for the 12 months to 30 September and 6
months to 31 March respectively.

 

As a result of this change in the accounting reference date, Nuformix's
reporting timetable will be as follows:

 

·    Unaudited interim results for the 12 months to 31 March 2023 to be
released by 30 June 2023;

 

·    Audited report and accounts for the 18 month period to 30 September
2023 published by 31 January 2023; and

 

·    Unaudited interim results for the six months to 31 March 2024 to be
released by 30 June 2024.

 

 

Enquiries:

 

 Nuformix plc
 Dr Dan Gooding, Executive Director                Via IFC Advisory

 Stanford Capital Partners Limited
 Tom Price / Patrick Claridge (Corporate Finance)  +44 (0) 20 3650 3650
 John Howes (Corporate Broking)                    +44 (0) 20 3650 3652

 IFC Advisory Limited
 Tim Metcalfe                                      +44 (0) 20 3934 6630

 Zach Cohen                                        nuformix@investor-focus.co.uk

 

About Nuformix

 

Nuformix is a pharmaceutical development company targeting unmet medical needs
in fibrosis and oncology via drug repurposing. The Company aims to use its
expertise in discovering, developing and patenting novel drug forms, with
improved physical properties, to develop new products in new indications that
are, importantly, differentiated from the original (by way of dosage, delivery
route or presentation), thus creating new and attractive commercial
opportunities. Nuformix has a pipeline of preclinical assets with potential
for significant value and early licensing opportunities.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NARFZGMFFMFGFZM